Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-12-17
2011-11-29
Dahle, Chun (Department: 1644)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S325000, C435S326000, C435S328000, C435S335000, C435S344100, C435S346000
Reexamination Certificate
active
08067564
ABSTRACT:
Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5993814 (1999-11-01), Williams et al.
patent: 6031080 (2000-02-01), Williams et al.
patent: 6403782 (2002-06-01), Luster et al.
patent: 6946546 (2005-09-01), Vaughan et al.
patent: 7265201 (2007-09-01), Ponath et al.
patent: 7323311 (2008-01-01), Vaughan et al.
patent: 7597889 (2009-10-01), Armour et al.
patent: 0 546 634 (1993-06-01), None
patent: 2 350 612 (2000-12-01), None
patent: WO 91/07492 (1991-05-01), None
patent: WO 93/02190 (1993-02-01), None
patent: WO 97/00960 (1997-01-01), None
patent: WO 97/12914 (1997-04-01), None
patent: WO 99/10534 (1999-03-01), None
patent: WO 01/14424 (2001-03-01), None
patent: WO 02/02640 (2002-01-01), None
Rudikoff et al. PNAS 1982 vol. 79, pp. 1979-1983.
Rader et al. PNAS. 1998. 95:8910-8915.
Cossins et al. Protein Expression and Purification 51 (2007) 253-259.
Holt et al. Trends in Biotechnology vol. 21 No. 11 Nov. 2003. pp. 484-490.
Colby et al. J. Mol. Biol. (2004) 342:901-912.
van den Beucken et al. J. Mol. Biol. (2001) 310:591-601.
Reiter et al. J. Mol. Biol. (1999) 290:685-698.
Marks et al. Biotechnology BioTechnology 10 (1992) pp. 779-783.
Xu et al. Immunity vol. 13, 37-45. Jul. 2000.
Gonzalo et al., “Eosinophil Recruitment to the Lung in a Murine Model of Allergic Inflammation—The Role of T Cells, Chemokines, and Adhesion Receptors,”J. Clin. Invest. 98(10):2332-2345, 1996.
Humbles et al., “Kinetics of Eotaxin Generation and Its Relationship to Eosinophil Accumulation in Allergic Airways Disease: Analysis in a Guinea Pig Model In Vivo,”J. Exp. Med. 186(4):601-612, 1997.
Jackson et al., “Antigen specificity and tumour targering efficiency of a human carcinoembryonic antigen-specific scFv and affinity-matured derivatives,”British Journal of Cancer 78(2):181-188, 1998.
Main et al., “A Potent Human Anti-Eoxtaxinl Antibody, CAT-213: Isolation by Phage Display and in Vitro and in Vivo Efficacy,”The Journal of Pharmacology and Experimental Therapeutics 319(3):1395-1404, 2006.
Bensimon, C. et al., “Human lupus anti-DNA autoantibodies undergo essentially primary Vχ gene rearrangements,”The EMBO Journal 13(13):2951-2962, 1994.
Ewert, S. et al., “Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering,”Methods 34:184-199, 2004.
Garcia-Zepeda, E. et al., “Human eotaxin is a specific chemoattractant for eosinophil cells an provides a new mechanism to explain tissue eosinophila,”Nat. Med. 4:449-456, 1996.
Genbank Acc. No. BAA08370 Eotaxin (Internet website—ncbi.nlm.nih.gov.), p. 1 May 2, 2003.
Griffiths-Johnson, D. et al., “The Chemokine, Eotaxin, Activates Guinea-Pig Eosinophils in vitro and Causes Their Accumulation into the Lung in vivo,”Biochemical and Biophysical Research Communications 197(3):1167-1172, 1993.
Harlow, E. et al., “Antibodies: A Laboratory Manual,” 1988 by Cold Spring Harbor Laboratory, pp. 560-562.
Jose, P. et al., “Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in a Guinea Pig Model of Allergic Airways Inflammation,”J. Exp. Med. 179:881-887, 1994.
Jose, P. et al., “Eotaxin: Cloning of an Eosinophil Chemoattractant Cytokine and Increased mRNA Expression in Allergen-Challenged Guinea-Pig Lungs,”Biochemical and Biophysical Research Communications 205(1):788-794, 1994.
Kitaura, M. et al., “Molecular Cloning of Human Eotaxin, an Eosinophil-selective CC Chemokine, and Identification of a Specific Eosinophil Eotaxin Receptor, CC Chemokine Receptor 3,”JBC 271(13):7725-7730, 1996.
Li, Y. et al., “Three-Dimensional Structures of the Free and Antigen-Bounds Fab from Monoclonal Antilysozyme Antibody HyHEL-63,”Biochemistry 39:6296-6309, 2000.
Nakajima, T. et al., “Intracellular localization and release of eotaxin from normal eosinophils,”FEBS Letters 434:226-230, 1998.
Pech, M. et al., “Organization and Evolution of a Gene Cluster for Human Immunoglobulin Variable Regions of the Kappa Type,”J. Mol. Biol. 176:189-204, 1984.
Ponath, P. et al., “Cloning of the Human Eoshinophil Chemoattractant, Eotaxin,”J. Clin. Invest. 97(3):604-612, 1996.
Main Sarah Helen
Smith Stephen
Vaughan Tristan John
Wilton Alison Jane
Dahle Chun
MedImmune Limited
LandOfFree
Methods of obtaining a specific binding member that binds... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of obtaining a specific binding member that binds..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of obtaining a specific binding member that binds... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4291422